Axsome Therapeutics Inc

AXSM remains in a Stage 2 advancing regime with strong medium- and long-term uptrends, yet recent Bullish Exhaustion and elevated Options Scores signal short-term overextension. Price is extended above the rising 9/20/50 EMA cluster, so execution should be deferred until a shallow pullback into that dynamic support zone. Continued trend integrity and EMA support hold will confirm a favorable entry environment.

• ↑Q4 2025 revenue surged 65% YoY to $196M, driven by Avelity sales.
• ↑Avelity generated over $500M in sales since launch, confirming strong market traction.
• ↓Negative earnings yield and weak book-to-price indicate possible overvaluation.